NCT05727163 2025-05-30
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03164655 2024-10-01
SULTAN
UNICANCER
Phase 2 Completed
NCT04169347 2023-07-27
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
Phase 2 Unknown
NCT04790448 2023-02-15
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT03751176 2021-06-30
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT03792269 2019-01-03
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT01882868 2017-03-14
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Phase 2 Completed
NCT01249638 2011-03-14
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Ludwig-Maximilians - University of Munich
Phase 3 Unknown